300177
By:
Joseph P. Costantino
|
9:35 AM 08/14/2002
|
Risk Assessment Modeling in Clinical Trials
|
300318
By:
Stephen J. Ruberg
|
9:50 AM 08/12/2002
|
A New Paradigm for Clinical Trials Afforded by Emerging Technologies
|
300167
By:
Andrew Briggs
|
10:35 AM 08/14/2002
|
We're Not Just Normal: Economists' View on Statistical Methods for Cost-Effectiveness Analysis
|
300168
By:
Dennis Fryback
|
11:00 AM 08/14/2002
|
Bayesian Methods in Cost-Effectiveness Analysis
|
300430
By:
Vance Berger
|
10:35 AM 08/13/2002
|
Use of the Reverse Propensity Score to Detect and Correct for Selection Bias in Clinical Trials
|
300108
By:
Mousumi Banerjee
|
9:15 AM 08/14/2002
|
Methods for Prognostic Stratification in Clinical Trials
|
300126
By:
James L. Kepner
|
4:30 PM 08/11/2002
|
Statistical Issues in Clinical Trials for Children with Cancer
|
300177
By:
Joseph P. Costantino
|
9:35 AM 08/14/2002
|
Risk Assessment Modeling in Clinical Trials
|
300318
By:
Stephen J. Ruberg
|
9:50 AM 08/12/2002
|
A New Paradigm for Clinical Trials Afforded by Emerging Technologies
|
300430
By:
Vance Berger
|
10:35 AM 08/13/2002
|
Use of the Reverse Propensity Score to Detect and Correct for Selection Bias in Clinical Trials
|
300486
By:
Kao-Tai Tsai
|
3:35 PM 08/12/2002
|
Q-TWiST Analysis for Neoadjuvant Cancer Trials
|
300510
By:
Yu Shen
|
9:35 AM 08/12/2002
|
Sample Size Re-estimation for Clinical Trials with Censored Survival Data
|
300516
By:
Vernon L. Chinchilli
|
10:35 AM 08/13/2002
|
Using Counterfactuals to Account for Treatment Failures in Clinical Trials
|
300524
By:
Ying-Kuen Cheung
|
11:20 AM 08/12/2002
|
Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials
|
300510
By:
Yu Shen
|
9:35 AM 08/12/2002
|
Sample Size Re-estimation for Clinical Trials with Censored Survival Data
|
300761
By:
Ruth H. Pfeiffer
|
2:50 PM 08/12/2002
|
On Meta-Analytic Assessment of Surrogate Outcomes
|
300556
By:
Amy S. Xia
|
08/13/2002
T-02
|
T-02
Bayesian Methods in the Medical Device Industry
|
300318
By:
Stephen J. Ruberg
|
9:50 AM 08/12/2002
|
A New Paradigm for Clinical Trials Afforded by Emerging Technologies
|
300614
By:
Chau Thach
|
10:55 AM 08/13/2002
|
Self-Designing Optimal Group Sequential Trials
|
300694
By:
Leslie A. McClure
|
9:20 AM 08/14/2002
|
Designing Clinical Trials When Treatments Favor Different Endpoints
|
300776
By:
Jonathan G. Levine
|
2:05 PM 08/11/2002
|
Inference in Multi-Center Clinical Trials When the Parameters are Known.
|
300225
By:
Sherryl Baker
|
2:30 PM 08/11/2002
|
Statistical Issues in Clinical Trials Involving Drug Addicted Patients
|
300798
By:
Gregory Russell Pond
|
3:05 PM 08/11/2002
|
Likelihood Methods for Phase II Clinical Trials
|
300830
By:
Naum M. Khutoryansky
|
9:35 AM 08/12/2002
|
Incremental Methods of Imputation in Longitudinal Clinical Trials
|
300880
By:
Tailiang Xie
|
11:05 AM 08/13/2002
|
Statistical Analysis of Complicated Adverse Event Data in Clinical Trials
|
300881
By:
Ratna Ramaswamy
|
10:55 AM 08/15/2002
|
Mixed-effects Modeling and Simulation of Longitudinal Clinical Trials with Informative Dropouts
|
300082
By:
Mike Proschan
|
2:25 PM 08/12/2002
|
Practical Mid-Course Sample Size Modification In Clinical Trials
|
300374
By:
Sue Marcus
|
2:55 PM 08/14/2002
|
Comparison of Propensity-Score-Adjusted Instrumental Variable Estimate with Intent-to-Treat Estimate in Randomized Clinical Trials with Noncompliance
|
300073
By:
Ron Brookmeyer
|
4:55 PM 08/11/2002
|
Measuring Dementia from Multidimensional Longitudinal Data
|
301178
By:
Yi Cheng
|
11:35 AM 08/12/2002
|
Asymptotic Optimal Sample Sizes for Discovering Promising Treatment in Phase II Group Sequential Clinical Trials.
|
301180
By:
Christopher H. Schmid
|
2:25 PM 08/12/2002
|
Using the Control Rate to Explore Heterogeneity of Treatment Effects in Clinical Trials
|
300376
By:
Mary Amanda Dew
|
9:05 AM 08/12/2002
|
QOL Assessment: Evolving Psychometric Issues and Approaches
|
301296
By:
Dongsheng Tu
|
12:05 PM 08/13/2002
|
A Comparison of Some Statistical Procedures for Therapeutic Equivalence Clinical Trials with Survival Endpoints
|
300047
By:
Michael Nessly
|
2:05 PM 08/14/2002
|
Is the Road to Drug Registration Paved with Good Intentions to Treat?
|
300377
By:
Stephanie R. Land
|
9:35 AM 08/12/2002
|
Assessment and Analysis of QOL Outcomes in Cancer Clinical Trials: The NSABP Experience
|
301406
By:
Christina Korkontzelou
|
2:05 PM 08/13/2002
|
Accounting for Informative Dropout in Longitudinal Clinical Trials of Smoking Cessation: Application of Inverse Probability Weighting and Sensitivity Analysis
|
300382
By:
Cindy L. Christiansen
|
2:30 PM 08/13/2002
|
Combining Information From Clinical Trials and Observational Studies to Evaluate Safety
|
301495
By:
Ghanshyam Gupta
|
10:35 AM 08/13/2002
|
A Review of Equivalence Testing in Clinical Trials
|
301895
By:
Mushfiquar Rashid
|
3:05 PM 08/11/2002
|
Rank-Based Methods for Clinical Trials With Unbalanced Repeated Measures Data
|
300093
By:
Richard De Veaux
|
10:35 AM 08/14/2002
|
Investigation of Drop Out Rates in Clinical Trials via Data Mining
|
301740
By:
Keaven M. Anderson
|
11:15 AM 08/15/2002
|
Simulation for Power and Type I Error Computation in Complex Trials: Some Examples
|
301793
By:
Shou-En Lu
|
11:35 AM 08/13/2002
|
Analyzing Excessive No Changes in Clinical Trials with Clustered Data
|
301831
By:
Russell W. Helms
|
4:05 PM 08/11/2002
|
Analysis Databases: An Overview
|
301832
By:
James D. Hosking
|
4:25 PM 08/11/2002
|
Public Use Databases: A Precursor To Analysis Databases
|
301833
By:
Lori Carter-Edwards
|
4:45 PM 08/11/2002
|
Scientific Issues Raised By Analysis Databases
|
301842
By:
Karen Wade
|
5:05 PM 08/11/2002
|
The Self-Documenting Database
|
301843
By:
Juliet A. Allen
|
5:25 PM 08/11/2002
|
Harnessing The Power Of Analysis Databases: The Necessity Of Appropriate Software
|
301850
By:
Heather R. Crosby
|
10:50 AM 08/13/2002
|
An Efficient Method of Subgrouping in Crossover Trials and its Performance Evaluation by Simulations
|
301865
By:
Gary L. Rosner
|
11:50 AM 08/12/2002
|
An Aid to Monitoring Phase II Studies in Cancer
|
301895
By:
Mushfiquar Rashid
|
3:05 PM 08/11/2002
|
Rank-Based Methods for Clinical Trials With Unbalanced Repeated Measures Data
|
300048
By:
Joseph W. Hogan
|
2:30 PM 08/14/2002
|
A Hierarchical Potential Outcomes Model for Estimating Both Causal and Intention-to-Treat Effects from Repeated Measures Under 'Double Sampling'
|
300374
By:
Sue Marcus
|
2:55 PM 08/14/2002
|
Comparison of Propensity-Score-Adjusted Instrumental Variable Estimate with Intent-to-Treat Estimate in Randomized Clinical Trials with Noncompliance
|
301895
By:
Mushfiquar Rashid
|
3:05 PM 08/11/2002
|
Rank-Based Methods for Clinical Trials With Unbalanced Repeated Measures Data
|
301927
By:
Mohamed Alosh
|
12:05 PM 08/12/2002
|
Testing for Treatment Effect in Clinical Trials with Multidimensional Longitudinal Data
|
|